MiR-148a inhibits angiogenesis by targeting ERBB3

Journal of Biomedical Research

Volumn 25, Issue 3, 2011, Pages 170-177

  Yu, Jing ^a   Li, Qi ^a   Xu, Qing ^a   Liu, Lingzhi ^a   Jiang, Binghua ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Breast cancer; ERBB3; MicroRNA 148a

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 148A; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CARCINOGENESIS; DOWN REGULATION; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ONCOGENE;

EID: 79959459891     PISSN: 16748301     EISSN: 16748301     Source Type: Journal    
DOI: 10.1016/S1674-8301(11)60022-5     Document Type: Article

References (37)

1. Lai EC Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002, 30:363-364.
2. Ambros V microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
3. Ryan BM, Robles AI, Harris CC Harris. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
5. Tchernitsa O, Kasajima A, Schafer R, Kuban RJ, Ungethum U, Gyorffy B, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 2010, 222:310-319.
6. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009, 114:3872-3879.
7. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010, 14:1170-1179.
8. Hummel R, Hussey DJ, Michael MZ, Haier J, Bruewer M, Senninger N, et al. MiRNAs and Their Association with Locoregional Staging and Survival Following Surgery for Esophageal Carcinoma. Ann Surg Oncol 2011, 18:253-260.
9. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Holland KB, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:5660-5669.
10. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microR-NA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008, 105:13556-13561.
11. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010, 285:19076-19084.
12. Murata T, Takayama K, Katayama S, Urano T, Ho-rie-Inoue K, Ikeda K, et al. miR-148a is an andro-gen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 2010, 13:356-361.
13. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R miR-148 targets human DNMT3b protein coding region. RNA 2008, 14:872-877.
14. Takagi S, Nakajima M, Mohri T, Yokoi T Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008, 283:9674-9680.
15. Braconi C, Huang N, Patel T MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 51:881-890.
16. Olayioye MA, Neve RM, Lane HA, Hynes NE The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
17. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat. Rev. Mol Cell Biol 2001, 2:127-137.
18. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992, 66:1116-1121.
19. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factori receptor in breast cancer cells resistant to herceptin. Cancer Res 2010, 70:1204-1214.
20. Wu H, Zhu S, Mo YY Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009, 19:439-448.
21. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007, 282:1479-1486.
22. Folkman J, Watson K, Ingber D, Hanahan D Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
23. Eilken HM, Adams RH Turning on the angiogenic microswitch. Nat Med 2010, 16:853-854.
24. Kamalati T, Jolin HE, Fry MJ, Crompton MR Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000, 19:5471-5476.
25. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
26. Folkman J Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
27. Lee DY, Deng Z, Wang CH, Yang BB Micro-RNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007, 104:20350-20355.
28. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008, 14:382-393.
29. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, et al. The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 2010, 70:8233-8246.
30. Hatake K, Tokudome N, Ito Y Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. Breast Cancer 2007, 14:132-149.
31. Navolanic PM, Steelman LS, McCubrey JA EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int. Oncol 2003, 22:237-252.
32. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster. Nat Genet 2006, 38:1060-1065.
33. Wang S, Huang X, Lee CK, Liu B Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236.
34. Semenza GL Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
35. Wang X A PCR-based platform for microRNA expression profiling studies. RNA 2009, 15:716-723.
36. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179.
37. Jiang BH, Zheng JZ, Aoki M, Vogt PK Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000, 97:1749-1753.